Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies

Taxane–gemcitabine combinations have demonstrated antitumor activity. This phase I study (NCT01001221) aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of cabazitaxel plus gemcitabine and to assess the preliminary efficacy of this combination. The patients incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Rixe, Olivier, Puzanov, Igor, LoRusso, Patricia M., Cohen, Roger B., Morris, John C., Olowokure, Olugbenga O., Yin, Jian Y., Doroumian, Séverine, Shen, Liji, Olszanski, Anthony J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Clinical Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484664/
https://www.ncbi.nlm.nih.gov/pubmed/26020806
http://dx.doi.org/10.1097/CAD.0000000000000250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484664/
https://www.ncbi.nlm.nih.gov/pubmed/26020806
http://dx.doi.org/10.1097/CAD.0000000000000250

Ejemplares similares